Drug development challenges and strategies to address emerging and resistant fungal pathogens.

Related Articles

Drug development challenges and strategies to address emerging and resistant fungal pathogens.

Expert Rev Anti Infect Ther. 2017 May 08;:

Authors: McCarthy MW, Walsh TJ

Abstract
INTRODUCTION: Invasive fungal infections represent an expanding threat to public health. The recent emergence of Candida auris, which is often resistant to existing antifungal agents and is associated with a high mortality rate, underscores the urgent need for novel drug development strategies. Areas covered: In this paper, we examine both challenges and opportunities associated with antifungal drug development and explore potential avenues to accelerate the development pipeline, including data sharing, surrogate endpoints, and the role of historical controls in clinical trials. Expert commentary: We review important lessons learned from the study of other rare diseases, including mitochondrial storage diseases and certain forms of cancer that may inform strategies to develop new antifungal agents while highlighting promising new compounds such as SCY-078 for the treatment of invasive fungal infections.

PMID: 28480775 [PubMed - as supplied by publisher]